MODERNA INC. DL-_0001
Commented by Stefan Feulner on September 6th, 2021 | 14:25 CEST
BASF, Desert Gold, Moderna, BioNTech - Keep going, keep going!
The Delta variant is teaching the markets to be afraid. After the economy was humming in the past two quarters, disillusionment is now slowly setting in. The unexpectedly weak labor market data in the US in August demonstrated this. Outside of agriculture, only 235,000 new jobs were created compared with the forecast of 728,000 new jobs. Thus, the market's fear of an end to loose monetary policy and possible interest rate hikes should also be off the table.
ReadCommented by Stefan Feulner on August 27th, 2021 | 11:53 CEST
BioNTech, XPhyto, Moderna - Boosters for the portfolio
Globally, infection numbers are rising dramatically due to the highly contagious Delta variant. According to the RKI, 12,626 new infections were reported in Germany alone, 4,226 more than a week ago. With the incidence rising above the authoritative level of 35, greater emphasis is again being placed on the rule, vaccinated, recovered or tested. As a result, demand for PCR or rapid tests is skyrocketing. Diagnostic companies, like vaccine producers, are in for a warm cash shower.
ReadCommented by Carsten Mainitz on August 16th, 2021 | 11:20 CEST
Defence Therapeutics, Moderna, Evotec - Bet on the front-runners!
Health is our most important asset. Biotech companies that protect it save not only human lives but also reap high profits. The price development of many biotech stocks over the past few months has been breathtaking. Investors are advised to focus on the frontrunners, as the market position gained as a first mover, the leadership position in a niche or innovative solution, will enable the companies to keep their competitors at bay for a long time to come.
ReadCommented by Stefan Feulner on July 8th, 2021 | 13:18 CEST
BioNTech, Defence Therapeutics, Moderna - The wheel keeps turning
After a hesitant start, Germany is making good progress with vaccinations. Around 47.5 million people, or 57.1% of the total population, have been vaccinated at least once. The number of fully vaccinated people rises to 39.9%. Rosy prospects for the summer in the republic. But now comes the Delta variant. According to initial studies, it is more resistant to the vaccines currently on the market than other variants. Research is continuing, and new manufacturers are entering the market to participate in the billion-dollar business.
ReadCommented by Stefan Feulner on January 28th, 2021 | 10:28 CET
Software AG, Upco International, Moderna - Here's the new WhatsApp!
WhatsApp is the world's leading messenger service, with over two billion users chatting, calling and sending photos to each other. However, by announcing that it was changing its privacy policy, the Facebook subsidiary has done itself a disservice. Users are now running away in droves. Competitor Telegram gained over 25 million new users within three days, and Signal was the most downloaded app in the Apple Store. Another company is also benefiting from the WhatsApp debacle, but this one can do much more than just Messenger.
ReadCommented by Stefan Feulner on January 27th, 2021 | 08:45 CET
Plug Power, Triumph Gold, Moderna - Take position before it's too late!
The new President of the United States, Joe Biden, and his predecessor, Donald Trump, have one thing in common: building up new mountains of debt. Just in time for his inauguration, the 46th President of the United States announced a new USD 1.9 trillion aid package for the economy and consumers. At some point, the extreme increase in global government and corporate and household debt will result in a major disaster. One way out is to invest in real assets. Position yourself now, before it is too late!
ReadCommented by Carsten Mainitz on January 12th, 2021 | 10:28 CET
CureVac, Q&M Dental, Moderna - What you didn't know - really exciting!
The World Health Organization (WHO) recorded more than 235 Covid-19 vaccine projects worldwide since January 2020, but few projects make it across the finish line. Timing is a critical factor, and early entrants will divide the huge market among themselves. These include BioNTech/Pfizer, Moderna and AstraZeneca. Still in the "test phase" is Tübingen-based CureVac, which recently entered into a sales cooperation with Bayer. Information published yesterday is positive and suggests approval of the preparation by the beginning of the second quarter of 2021 at the latest. Away from vaccine manufacturers, other Corona profiteers exist with which investors can earn handsomely. Q&M Dental from Singapore is little known. Its subsidiary is one of nine government-approved Corona testing facilities. Also, Q&M supplies Asian neighboring countries with millions of its Corona testing. We inform you about the news and potentials of known and unknown players.
ReadCommented by André Will-Laudien on December 23rd, 2020 | 08:50 CET
Q & M Dental, Moderna, AstraZeneca: Serving people!
Rarely has the stock market been so focused on people as it has been during the pandemic. People are thinking about which companies offer the best service package for all the problems associated with infections, vaccinations and even the psychological effects of isolation and loneliness. Humans are "social animals" with multiple social needs. Curtailing these needs works temporarily, but at some point, the arguments have to be genuinely purposeful so that certain restrictions continue to be accepted. At the peak of the contagion curve, we would like to see possible remedies that quickly turn the overall situation into a positive end - this is possible for the medium-term future. Still, in the short term, we have to stick together.
ReadCommented by Stefan Feulner on December 15th, 2020 | 15:37 CET
Moderna, AdTiger, AstraZeneca - here we go!
The announcement of the second lockdown last Sunday is a disaster for brick-and-mortar retailers. After an extremely sluggish Christmas season so far, the new closures will turn off the lights for stores during the most critical time of the year. Of the total 560,000 jobs in downtown retail, up to 250,000 are said to be acutely threatened. The beneficiary of this disastrous situation is once again, eCommerce. However, in addition to the major platforms Amazon, Alibaba or Zalando, other Internet companies are also profiting from the online trend.
ReadCommented by Nico Popp on December 9th, 2020 | 14:16 CET
Valeo Pharma, CureVac, Moderna, Sartorius: high-flyers or latecomers?
The pandemic continues to spread: Germany is now facing a complete lockdown. Meanwhile, there is good news from the vaccine and drug manufacturers. There are several vaccines available, and from 2021 onwards, vaccination programs are to be implemented rapidly in all industrialized countries. Nevertheless, question marks remain: How long a vaccination will protect a person remains to be seen. For this reason, drugs and other measures to treat patients successfully remain essential. One of these drugs has just received approval from the Canadian regulatory authorities.
Read